Hepatitis A – Drug Pipeline Landscape, 2023
Hepatitis A is an inflammation of the liver caused by the hepatitis A virus (HAV). The virus is primarily spread when an uninfected (and unvaccinated) person ingests food or water that is contaminated with the faeces of an infected person.
Hepatitis A caused by taking the food prepared by someone with the hepatitis A virus, taking sewage-contaminated raw shellfish, drinking polluted water, and having sex with someone who has the hepatitis A virus.
Signs and symptoms of Hepatitis A range from mild to severe and can include fever, malaise, loss of appetite, diarrhoea, nausea, abdominal discomfort, dark-coloured urine, and jaundice (a yellowing of the eyes and skin), unexplained weight loss.
Doctors most often diagnose Hepatitis A by asking symptoms, physical examination and by detection of HAV-specific immunoglobulin G (IgM) antibodies in the blood. The tests include reverse transcriptase polymerase chain reaction (RT-PCR) to detect the hepatitis A virus RNA and blood test for levels of liver enzymes.
The most common investigative treatments of Hepatitis A include Hepatitis A vaccine which can prevent infection with the virus. Symptoms can be eased through lifestyle changes and good hygiene.
Global Insight Service’s, Hepatitis A – Drug Pipeline Landscape, 2023 report provides an overview of the Hepatitis A pipeline drugs. This report covers detailed insights on Hepatitis A drugs under development, assessment by target, mechanism of action, route of administration and molecule type.Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Hepatitis A pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Reasons to Buy
- Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
- Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
- Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
- Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Table of Contents
List of Tables
List of Figures
1.1 Hepatitis A – Pipeline Drugs, 2023 – Coverage
2. Disease Overview – Hepatitis A
2.2 Signs and Symptoms
2.4 Disease Management
3. Hepatitis A – Pipeline Drugs Development – Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2023
3.3 Products under Development by Companies, 2023
4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.3 Assessment by Route of Administration
5. Drug Profiles
5.1 Clinical Stage Drugs – Phase III
5.1.1 Hepatitis A Vaccine
5.1.2 Inactivated Hepatitis A Vaccine
5.2 Clinical Stage Drugs – Phase II
5.2.1 Boryung Hepatitis A Vaccine (Children)
5.3 Clinical Stage Drugs – Phase I
5.4 Early-Stage Drugs – Preclinical
5.4.1 Hepatitis A Vaccine
6. Key Regulatory Designations
7. Key Deals
8. Key Upcoming Milestones
9. Key Companies Involved
9.1 Biological E Ltd
9.2 Boryung Pharmaceutical Co Ltd
9.3 Indian Immunologicals Ltd
9.4 SK Bioscience Ltd
9.5 Zydus Lifesciences Ltd
10. Dormant Drugs
10.1 Inactive Drugs
10.2 Discontinued Drugs
List of Tables
Table 1.1 Number of Products Under development for Hepatitis A
Table 1.2 Number of Products under Development by Companies
Table 1.3 Products under Development by Companies
Table 1.4 Products by Targets
Table 1.5 Products by Mechanism of Action
Table 1.6 Products by Molecule Type
Table 1.7 Products by Route of Administration
Table 2.1 Clinical Trial Details – Hepatitis A vaccine/Biological E Ltd
Table 2.2 Clinical Trial Details – Inactivated Hepatitis A Vaccine/Indian Immunologicals Ltd
Table 2.3 Clinical Trial Details – Boryung Hepatitis A Vaccine (Children)/Boryung Pharmaceutical Co Ltd
Table 2.4 Clinical Trial Details – ZYIL1/Zydus Lifesciences Ltd
Table 3.1 Regulatory Designations
Table 4.1 Inactive Drugs
List of Figures
Figure 1.1 Number of Products under Development for Hepatitis A, 2023
Figure 1.2 Products by Top 5 Targets and Stage of Development for Hepatitis A, 2023
Figure 1.3 Products by Top 5 Mechanism of Action and Stage of Development for Hepatitis A, 2023
Figure 1.4 Products by Top 5 Molecule Type and Stage of Development for Hepatitis A, 2023
Figure 1.5 Products by Top 5 Route of Administration and Stage of Development for Hepatitis A, 2023
- Assessment by Stage of Development
- Assessment by Companies
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Molecule Type
- Assessment by Route of Administration